Valion Bio, Inc.
VBIO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$74.36K
Close$
$5.36
874.1% upside
Current Fair Value
874.1% upsideUndervalued by 874.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $74,359.00 |
|---|---|
| Enterprise Value | $7.99 Million |
| Earnings per Share | $-7.84 |
| Beta | 1.8 |
| Outstanding Shares | 135,199 |
Return
| Return on Equity | -232.50% |
|---|---|
| Return on Assets | -30.40% |
| Return on Invested Capital | -37.11% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | -0.28 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | -51.2 |
| Enterprise Value to EBIT | -0.73 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.25 |
| Debt to Equity | 2.36 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-85.00
Consensus analyst estimateRevenue Estimate
$1.43 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Valion Bio, Inc.
52 employees
CEO: Michael R. Cavanaugh
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimo...